Infant Bacterial Therapeutics AB (OSTO:IBT B) EV-to-Revenue : (As of May. 04, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Infant Bacterial Therapeutics AB's enterprise value is kr551.22 Mil. Infant Bacterial Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00 Mil. Therefore, Infant Bacterial Therapeutics AB's EV-to-Revenue for today is .

The historical rank and industry rank for Infant Bacterial Therapeutics AB's EV-to-Revenue or its related term are showing as below:

During the past 11 years, the highest EV-to-Revenue of Infant Bacterial Therapeutics AB was 15600.64. The lowest was -2241.18. And the median was 2121.37.

OSTO:IBT B's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.895
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-04), Infant Bacterial Therapeutics AB's stock price is kr57.50. Infant Bacterial Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was kr0.00. Therefore, Infant Bacterial Therapeutics AB's PS Ratio for today is .

Infant Bacterial Therapeutics AB EV-to-Revenue Historical Data

The historical data trend for Infant Bacterial Therapeutics AB's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Infant Bacterial Therapeutics AB EV-to-Revenue Chart

Infant Bacterial Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

Get a 7-Day Free Trial

Infant Bacterial Therapeutics AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Infant Bacterial Therapeutics AB's EV-to-Revenue

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Infant Bacterial Therapeutics AB's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Infant Bacterial Therapeutics AB EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Infant Bacterial Therapeutics AB's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	551.219	/	0
	=

Infant Bacterial Therapeutics AB's current Enterprise Value is kr551.22 Mil.
Infant Bacterial Therapeutics AB's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

Infant Bacterial Therapeutics AB (OSTO:IBT B) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Infant Bacterial Therapeutics AB's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	57.50	/	0
	=

Infant Bacterial Therapeutics AB's share price for today is kr57.50.
Infant Bacterial Therapeutics AB's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00.

Infant Bacterial Therapeutics AB EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Infant Bacterial Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (OSTO:IBT B) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

9IB:Germany

Address

Bryggargatan 10, Stockholm, SWE, 111 21

Website

https://www.ibtherapeutics.com

Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.

Infant Bacterial Therapeutics AB Headlines

No Headlines